DK2145189T3 - Papillomavirus-pseudovira til detektion og behandling af tumorer - Google Patents

Papillomavirus-pseudovira til detektion og behandling af tumorer Download PDF

Info

Publication number
DK2145189T3
DK2145189T3 DK08747407.8T DK08747407T DK2145189T3 DK 2145189 T3 DK2145189 T3 DK 2145189T3 DK 08747407 T DK08747407 T DK 08747407T DK 2145189 T3 DK2145189 T3 DK 2145189T3
Authority
DK
Denmark
Prior art keywords
papilloma
vlp
pseudovirus
cancer
carcinoma
Prior art date
Application number
DK08747407.8T
Other languages
English (en)
Inventor
Douglas R Lowy
John T Schiller
Jeff Roberts
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK2145189T3 publication Critical patent/DK2145189T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Claims (16)

1. Papilloma-pseudovirus eller papilloma-VLP omfattende et detekterbart mærke til anvendelse i en fremgangsmåde til detektering af forekomst af kræftceller hos et individ, der har eller mistænkes for at have kræftceller, hvor fremgangsmåden omfatter: at identificere et individ, der har eller mistænkes for at have kræftceller, at administrere en detekterbar mængde af papilloma-pseudovirusset eller papilloma-VLP'en, der omfatter et detekterbart mærke, til individet, og at detektere forekomst af kræftceller, der er bundet til papilloma-pseudovirusset eller papilloma-VLP'en, som omfatter et detekterbart mærke.
2. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge krav 1, hvor detekteringen udføres på et individ før en kræftterapibehandling og under eller efter et tidsrum med behandlingen.
3. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge krav 1 eller 2, hvor mærket er kemisk koblet til pseudovirusset eller VLP'en, eller pseudovirusset omfatter et gen, der koder for mærket.
4. Sammensætning omfattende et terapeutisk middel, der er formuleret med et papilloma-pseudovirus eller en papilloma-VLP, til anvendelse i en fremgangsmåde til behandling af kræft ved at hæmme proliferation af kræftceller og/eller at dræbe kræftceller uden at hæmme proliferation og/eller at dræbe normale celler hos et individ, der har fået konstateret kræft, hvor det terapeutiske middel er cytotoksisk for en kræftcelle.
5. Sammensætning til anvendelse ifølge krav 4, hvor det terapeutiske middel er kemisk koblet til pseudovirusset eller VLP'en eller er inkorporeret i pseu-dovirusset eller VLP'en.
6. Sammensætning til anvendelse ifølge krav 4 eller 5, hvor det terapeutiske middel er valgt fra gruppen bestående af: a) et gen, der er valgt fra gruppen bestående af: i) et tumorundertrykkende gen, ii) et proapoptotisk gen, iii) et gen, der koder for et cytokin, et lymphokin, et monokin, en vækstfaktor, et enzym eller et hormon, iv) et immunomodulatorisk gen, v) et gen, der koder for et polypeptid, der er cytotoksisk for en kræftcelle, og vi) et selvmordsgen, b) et cytotoksin, c) et radionuklid, d) et prodrug og e) en terapeutisk nukleinsyre.
7. Sammensætning til anvendelse ifølge krav 4 eller 5, hvor det terapeutiske middel er valgt fra gruppen bestående af ganciclovir eller acyclovir, oligo T og en nukleinsyre, der udtrykker oligo T, hvor nukleinsyren er operabelt forbundet med en Pol lll-promoter.
8. Sammensætning til anvendelse ifølge krav 7, hvor nævnte oligo T er mindre end eller lig med 200, 175, 150, 125, 100, 95, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15 eller 10 nukleotider.
9. Papilloma-pseudovirus og papilloma-VLP til anvendelse i en fremgangsmåde til detektering af forekomsten af kræftceller ifølge et hvilket som helst af kravene 1 til 3, eller sammensætning til anvendelse i fremgangsmåden til behandling af kræft ifølge et hvilket som helst af kravene 4 til 8, hvor kræfttypen er valgt fra gruppen bestående af leukæmi, lymfom, myelom, plasmacy-tom, fibrosarkom, myxosarkom, liposarkom, chondrosarkom, osteogent sarkom, chordom, angiosarkom, endotheliosarkom, lymphangiosarkom, lymp-hangioendothelsarkom, synoviom, mesotheliom, Ewings tumor, leiomyosar-kom, rhabdomyosarkom, kolonkarcinom, pankreaskræft, brystkræft, æggestokkræft, prostatakræft, pladecellekarcinom, basalcellekarcinom, epidermo-idkarcinom, adenokarcinom, svedkirtelkarcinom, talgkirtelkarcinom, papillært karcinom, papillære adenokarcinomer, cystadenokarcinom, medullært karci-nom, bronchogent karcinom, nyrecellekarcinom, hepatom, galdevejskarci-nom, choriokarcinom, seminom, embryonalt karcinom, Wilms' tumor, livmoderhalskræft, testikeltumor, lungekarcinom, småcellet lungekarcinom, blære-karcinom, epitelkarcinom, gliom, astrocytom, medulloblastom, kraniofaryn-geom, ependymom, pinealom, hemangioblastom, akustisk neurom, oligo- dendrogliom, meningiom, melanom, neuroblastom, neurogliom og retinobla-stom.
10. Kit omfattende et papilloma-pseudovirus eller en papilloma-VLP, en farmaceutisk bærer og vejledning til anvendelse af kitdelene, hvor pseudovirus-set eller VLP'en omfatter et terapeutisk middel, der er cytotoksisk for en kræftcelle.
11. Papilloma-pseudovirus eller papilloma-VLP omfattende et detekterbart mærke til anvendelse i en fremgangsmåde til detektering af forekomst af livmoderhalskræftceller hos et individ, hvor fremgangsmåden omfatter: at tilvejebringe en sammensætning til individet, der omfatter en papilloma-VLP, der er koblet til eller indeholder et mærke; at fjerne ubundne VLP'er, der omfatter mærket; og at detektere forekomst af kræftceller, der er bundet til VLP'en, som omfatter mærket.
12. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge krav 11, hvor mærket er kemisk koblet til VLP'en.
13. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge et hvilket som helst af kravene 1,2, 3, 11 eller 12, endvidere omfattende at måle forekomsten eller mængden af pseudovirusset eller VLP'en, der er bundet til kræftcellerne, og forekomsten eller mængden af pseudovi russet eller VLP'en, der er bundet til normale celler.
14. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge et hvilket som helst af kravene 1,2, 3,11 eller 12, hvor mærket er fluorescerende.
15. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge et hvilket som helst af kravene 1,2,3,11 eller 12, hvor mærket er radioaktivt.
16. Papilloma-pseudovirus eller papilloma-VLP til anvendelse ifølge et hvilket som helst af kravene 1,2, 3, 11 eller 12, hvor mærket er kemiluminesceren-de.
DK08747407.8T 2007-05-08 2008-05-01 Papillomavirus-pseudovira til detektion og behandling af tumorer DK2145189T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92849507P 2007-05-08 2007-05-08
US6589708P 2008-02-14 2008-02-14
PCT/US2008/062296 WO2008140961A2 (en) 2007-05-08 2008-05-01 Papillomavirus pseudoviruses for detection and therapy of tumors

Publications (1)

Publication Number Publication Date
DK2145189T3 true DK2145189T3 (da) 2016-06-06

Family

ID=39832293

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08747407.8T DK2145189T3 (da) 2007-05-08 2008-05-01 Papillomavirus-pseudovira til detektion og behandling af tumorer

Country Status (13)

Country Link
US (4) US8394411B2 (da)
EP (1) EP2145189B1 (da)
AU (1) AU2008251615B2 (da)
CA (1) CA2686990C (da)
CY (1) CY1117708T1 (da)
DK (1) DK2145189T3 (da)
ES (1) ES2575364T3 (da)
HR (1) HRP20160764T1 (da)
HU (1) HUE030437T2 (da)
PL (1) PL2145189T3 (da)
PT (1) PT2145189E (da)
SI (1) SI2145189T1 (da)
WO (1) WO2008140961A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2145189E (pt) 2007-05-08 2016-06-16 Us Health Pseudovírus de papilomavírus para deteção e terapêutica de tumores
US20100222417A1 (en) * 2008-11-26 2010-09-02 Alnylam Pharmaceuticals Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
US20120225090A1 (en) * 2009-08-03 2012-09-06 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP3046583B1 (en) * 2013-09-18 2019-02-13 Aura Biosciences, Inc. Virus-like particle conjugates for treatment of tumors
US10588972B2 (en) * 2014-06-02 2020-03-17 Li-Cor, Inc. Phthalocyanine probes and uses thereof
CN104880555B (zh) * 2015-06-19 2017-11-14 中国食品药品检定研究院 一种人乳头瘤病毒中和抗体的高通量检测方法
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US10751398B2 (en) * 2016-10-07 2020-08-25 Loyola University Chicago Inflammasome activators and methods of use to treat tumors
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
JP2020524710A (ja) 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
KR20250044945A (ko) 2017-11-06 2025-04-01 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
US11891426B2 (en) 2017-12-15 2024-02-06 Aleta Biotherapeutics Inc. CD19 variants
EP3752605A4 (en) * 2018-02-14 2021-12-15 The University of Houston System PROBE FOR UNIVERSAL DETECTION OF CIRCULATING TUMOR CELLS
WO2020113063A1 (en) 2018-11-30 2020-06-04 Aleta Biotherapeutics Inc. Single domain antibodies against cll-1
AU2019414934A1 (en) 2018-12-27 2021-06-24 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CN113881636B (zh) * 2020-07-03 2024-05-03 贝勒知临(杭州)生物技术有限公司 一种游离细胞标记及分离探针及其相关产品和用途
CA3195963A1 (en) 2020-10-19 2022-04-28 Joshua Weiyuan WANG Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
CA3235894A1 (en) 2021-10-25 2023-05-04 Brile Chung Compositions and methods for therapeutic delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1018875A (en) 1911-02-13 1912-02-27 Francois Edouard Cardon Finger-ring construction.
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
EP1015561B1 (en) * 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
PT2145189E (pt) 2007-05-08 2016-06-16 Us Health Pseudovírus de papilomavírus para deteção e terapêutica de tumores

Also Published As

Publication number Publication date
US20190290782A1 (en) 2019-09-26
CA2686990A1 (en) 2008-11-20
SI2145189T1 (sl) 2016-08-31
US8394411B2 (en) 2013-03-12
PL2145189T3 (pl) 2016-09-30
US8999290B2 (en) 2015-04-07
EP2145189A2 (en) 2010-01-20
HUE030437T2 (en) 2017-05-29
US20130230456A1 (en) 2013-09-05
CA2686990C (en) 2018-04-24
EP2145189B1 (en) 2016-04-06
WO2008140961A2 (en) 2008-11-20
AU2008251615A1 (en) 2008-11-20
HRP20160764T1 (hr) 2016-08-12
CY1117708T1 (el) 2017-05-17
WO2008140961A3 (en) 2009-06-18
US20150157738A1 (en) 2015-06-11
PT2145189E (pt) 2016-06-16
US20100135902A1 (en) 2010-06-03
US10188751B2 (en) 2019-01-29
AU2008251615B2 (en) 2014-09-18
US10814014B2 (en) 2020-10-27
ES2575364T3 (es) 2016-06-28

Similar Documents

Publication Publication Date Title
US10814014B2 (en) Papillomavirus pseudoviruses for detection and therapy of tumors
US8658778B2 (en) hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
US10080774B2 (en) Oncolytic adenovirus armed with therapeutic genes
JP5479087B2 (ja) アデノ随伴ウイルスファージ粒子に関する方法および組成物
US7754430B2 (en) Papilloma virus capsomere vaccine formulations and methods of use
CN101171337A (zh) 与基因表达的体内成像相关的方法和组合物
US11541119B2 (en) Tumor treatment methods using cells that localize to the tumor
US20070292396A1 (en) Combination therapy with oncolytic adenovirus
WO2023173114A2 (en) Recombinant virus-like particle capsid vaccines against adenoviruses and compositions, methods, and use thereof
Miletic et al. Oncolytic Herpes SimplexVirusType-1Therapy in a Highly Infiltrative Animal Model of Human Glioblastoma